Despite recent therapeutic advances, many cancer patients soon develop resistance to currently available treatment options. Thus, new treatment strategies are urgently needed to prevent or overcome therapy resistance. Developing such novel strategies requires a deep understanding of the cancer-driving events and the underlying molecular mechanisms of resistance.
To identify new drug targets and explore novel therapeutic strategies, we use a wide range of state-of-the-art laboratory techniques (including various CRISPR/Cas9 genome engineering technologies) and diverse in vitro and in vivo pre-clinical cancer models. A main focus of our interdisciplinary research is the interplay between oncogenic modulations and the de-regulation of programmed cell death (apoptosis) and how it can be targeted.